Bruker Co. (NASDAQ:BRKR) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its position in Bruker Co. (NASDAQ:BRKR - Free Report) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 222,439 shares of the medical research company's stock after selling 12,500 shares during the quarter. New York State Common Retirement Fund owned about 0.15% of Bruker worth $15,362,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BRKR. Nisa Investment Advisors LLC lifted its holdings in Bruker by 20.0% in the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company's stock valued at $63,000 after acquiring an additional 165 shares during the last quarter. Securian Asset Management Inc. lifted its stake in shares of Bruker by 2.3% in the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company's stock valued at $496,000 after purchasing an additional 175 shares during the last quarter. Covestor Ltd grew its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company's stock worth $34,000 after purchasing an additional 210 shares during the period. First Horizon Advisors Inc. increased its position in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock worth $25,000 after purchasing an additional 218 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Bruker by 0.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company's stock valued at $1,972,000 after buying an additional 235 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Stock Down 3.8 %

Bruker stock traded down $2.36 during trading on Wednesday, reaching $58.98. The stock had a trading volume of 2,014,907 shares, compared to its average volume of 1,071,632. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker Co. has a 52-week low of $54.55 and a 52-week high of $94.86. The stock has a market cap of $8.93 billion, a PE ratio of 24.98, a P/E/G ratio of 2.32 and a beta of 1.20. The business has a 50 day moving average price of $64.08 and a 200 day moving average price of $66.56.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business's revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 EPS. On average, analysts predict that Bruker Co. will post 2.61 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date was Friday, August 30th. Bruker's dividend payout ratio (DPR) is 8.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BRKR shares. Wells Fargo & Company dropped their price target on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday. Wolfe Research lowered Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. TD Cowen lowered their price target on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday. Citigroup cut their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, The Goldman Sachs Group lowered their target price on Bruker from $72.00 to $60.00 and set a "sell" rating for the company in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.